https://pharmadog.xyz/news/534791 pharmadog en 2026-10-13T10:34:16.000Z Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings https://pharmadog.xyz/news/534767 pharmadog en 2026-10-13T10:25:02.000Z Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failure https://pharmadog.xyz/news/534768 pharmadog en 2026-10-13T10:19:03.000Z Roche's seventh China deal this year is a $1.2B obesity pact with Rona Therapeutics https://pharmadog.xyz/news/534476 pharmadog en 2026-10-13T08:30:00.000Z Safety concerns rise as Neurocrine's Prader-Willi drug linked to deaths and hospitalizations https://pharmadog.xyz/news/534477 pharmadog en 2026-10-13T08:30:00.000Z Physicians Face Learned Helplessness From Training Culture, Says STAT+ Columnist https://pharmadog.xyz/news/534475 pharmadog en 2026-10-13T08:30:00.000Z Botched lethal injection of Christa Pike raises questions about execution protocols https://pharmadog.xyz/news/534406 pharmadog en 2026-10-13T03:24:00.000Z Nurix halts development of BTK degrader zelebrudomide after phase 1 review https://pharmadog.xyz/news/532431 pharmadog en 2026-10-12T21:26:00.000Z First Tracks reports positive early-stage results for celiac drug ANB033 https://pharmadog.xyz/news/531943 pharmadog en 2026-10-12T18:18:36.000Z Merck's diabetic eye-disease drug hits primary goal but faces commercial doubts https://pharmadog.xyz/news/531775 pharmadog en 2026-10-12T17:08:13.000Z Asahi Kasei Therapeutics receives FDA approval for HSV drug acquired in $1 billion deal https://pharmadog.xyz/news/531671 pharmadog en 2026-10-12T15:58:00.000Z Aspen Neuroscience files for Nasdaq IPO to fund Parkinson’s cell therapy program https://pharmadog.xyz/news/531415 pharmadog en 2026-10-12T15:35:00.000Z Bristol Myers' lung drug admilparant meets Phase 3 goal at low dose, high dose falls short https://pharmadog.xyz/news/531351 pharmadog en 2026-10-12T15:12:41.000Z Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefit https://pharmadog.xyz/news/531375 pharmadog en 2026-10-12T15:04:54.000Z BMS lung drug meets low-dose endpoint in Phase 3 but high dose fails to improve lung function https://pharmadog.xyz/news/531352 pharmadog en 2026-10-12T15:04:37.000Z Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drug https://pharmadog.xyz/news/531183 pharmadog en 2026-10-12T14:52:00.000Z Bausch + Lomb CEO Brent Saunders abruptly departs after failed multibillion-dollar sale https://pharmadog.xyz/news/531184 pharmadog en 2026-10-12T14:48:57.000Z GSK allocates over $800 million to expand R&D and manufacturing hub in Pennsylvania https://pharmadog.xyz/news/531039 pharmadog en 2026-10-12T13:34:43.000Z RevMed's pancreatic cancer drug Rasonque shows mixed results across KRAS subtypes, analysts stay optimistic https://pharmadog.xyz/news/531040 pharmadog en 2026-10-12T13:24:52.000Z BMS reports Phase 3 success for RYZ101 in GEP-NET trial https://pharmadog.xyz/news/531079 pharmadog en 2026-10-12T13:16:00.000Z Pharma faces $500B risk as patents expire, with Merck most exposed by 2028 https://pharmadog.xyz/news/531674 pharmadog en 2026-10-12T12:09:00.000Z Bausch + Lomb appoints board chair Thomas Appio as interim CEO after Brent Saunders departs https://pharmadog.xyz/news/530703 pharmadog en 2026-10-12T11:21:45.000Z GSK to invest $800 million in new biologics manufacturing hub in Pennsylvania https://pharmadog.xyz/news/530679 pharmadog en 2026-10-12T11:00:35.000Z Undecimal Bio raises $18 million to expand siRNA platform beyond liver diseases https://pharmadog.xyz/news/530990 pharmadog en 2026-10-12T09:42:00.000Z Roche reports updated eye drug data and FDA filing acceptance, targets July 2027 decision https://pharmadog.xyz/news/530991 pharmadog en 2026-10-12T09:25:00.000Z Tortugas Neuroscience's obuprazine shows significant improvement in phase 2b schizophrenia trial in China https://pharmadog.xyz/news/530822 pharmadog en 2026-10-12T08:06:00.000Z BMS reports phase 3 successes in IPF drug and neuroendocrine tumor radiotherapy https://pharmadog.xyz/news/530031 pharmadog en 2026-10-12T07:00:00.000Z Strategic CDMO partnerships shift from transactional to collaborative, emphasizing risk sharing and regulatory expertise https://pharmadog.xyz/news/529587 pharmadog en 2026-10-12T05:01:00.000Z Integrating Multiple Stability Measurements Improves Early Biologics Testing https://pharmadog.xyz/news/529982 pharmadog en 2026-10-12T02:55:00.000Z Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potential https://pharmadog.xyz/news/532612 pharmadog en 2026-10-12T00:00:00.000Z FDA approves new treatments for persistent herpes and schizophrenia; Steris to acquire Xodus Medical for $2.1 billion https://pharmadog.xyz/news/532609 pharmadog en 2026-10-12T00:00:00.000Z Europe’s share of clinical trials falls 13.5% as Asia’s research footprint expands https://pharmadog.xyz/news/532610 pharmadog en 2026-10-12T00:00:00.000Z FDA finalizes guidance aligning biosimilar post-approval manufacturing changes with global standards https://pharmadog.xyz/news/532611 pharmadog en 2026-10-12T00:00:00.000Z Japan's PMDA Issues Guidance to Safeguard Participants in Generic Bioequivalence Trials https://pharmadog.xyz/news/528111 pharmadog en 2026-10-11T21:00:05.000Z AstraZeneca attributes Phase 3 failure of bone disease enzyme therapy to trial design flaws